Other languages Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Market Closed - Nasdaq Other stock markets 21:00:00 29/04/2024 BST			5-day change	1st Jan Change
147.4 ^USD	+2.83%		+1.08%	-23.01%

04-08	Sector Update: Health Care Stocks Flat to Higher Premarket Monday	MT
04-08	Sector Update: Health Care	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Flat to Higher Premarket Monday	04-08
Sector Update: Health Care	04-08
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Chevron, Take-Two, Coinbase, Netflix, American Tower...	04-08
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint	04-08
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	04-07
ETF der Woche: Auf die Wende der Biotechs setzen	03-10
L'ETF della settimana: scommettere sull'inversione di tendenza delle biotech	03-09
ETF van de week: inzetten op de ommekeer in de biotech	03-08
ETF de la semaine : miser sur le retournement des Biotechs	03-08
Alnylam meldet positive KARDIA-2 Topline-Studienergebnisse, die eine klinisch signifikante Blutdrucksenkung bei Zugabe von Zilebesiran zu Standard-Blutdrucksenkern belegen	03-06
Alnylam annonce des résultats positifs de l’étude KARDIA-2 démontrant des réductions cliniquement significatives de la pression artérielle lorsque le zilebesiran est ajouté à des antihypertenseurs standards	03-05
Alnylam Pharmaceuticals Says Phase 2 Study of Hypertension Drug Zilebesiran Meets Primary Endpoint	03-05
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives	03-05
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,540,071, According to a Recent SEC Filing	03-01
Alnylam Pharmaceuticals Insider Sold Shares Worth $455,357, According to a Recent SEC Filing	02-29
RECOMENDACIONES DE LOS ANALISTAS EE.UU. : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever....	02-21
Alnylam Pharmaceuticals' Shares Fall on Q4 Revenue Miss	02-15
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	02-15
Alnylam Pharmaceuticals Q4 Non-GAAP Loss Narrows, Revenue Rises	02-15
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Other languages

Filters